Mumbai: Pharma major Lupin Limited (Lupin) announced the completion of the United States Food and Drug Administration (U.S. FDA) inspection carried out at its Aurangabad manufacturing facility. The inspection was carried out from May 6 to May 15, 2019.

The inspection at the Aurangabad facility closed with three observations. The Company is confident of addressing them satisfactorily.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded and generic formulations, biosimilar products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8^th largest generics pharmaceutical company by revenues (31^st Dec 2018, Bloomberg LTM). The Company is the 3^rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT Mar 2019); 3^rd largest Indian pharmaceutical company by global revenues (31^st Dec 2018, Bloomberg LTM); 5^th largest company in the Indian Pharmaceutical Market and 6^th largest generic pharmaceutical player in Japan (IQVIA MAT Mar 2019).

For the financial year ended 31^st March 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter at – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3^rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66408237

*Safe Harbor Statement